Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma

Inclusion Criteria:

* Patients having relapsed/refractory multiple myeloma and neuropathy (or who are otherwise unable to tolerate bortezomib)
* Aged 18 years and older
* Patient able to provide written, informed consent to participate in and follow the KEAP Treatment Plan

Exclusion Criteria:

* Known hypersensitivity to selinexor or any excipients.
* Patient receiving any other investigational agent.
* Any concurrent uncontrolled and active medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.).
* Known intolerance, hypersensitivity, or contraindication to glucocorticoids.
* Active graft versus host disease (after allogeneic stem cell transplantation).
* Active, unstable cardiovascular function:

  * Symptomatic ischemia, or uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics)
  * Congestive heart failure of New York Heart Association Class ≥ 3 or known leftventricular ejection fraction \< 40%, or
  * Myocardial infarction within 3 months prior to C1D1.
* Significant renal impairment with ongoing dialysis treatment
* Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could, in the treating physician's opinion, interfere with absorption of treatment.
* Any active, serious psychiatric, medical, or other conditions/situations which, in the treating physician's opinion, could compromise the patient's safety.